Kardium Announces First US Procedures in PULSAR Study of Globe® Pulsed Field System
The PULSAR study will enroll over 400 patients for treatment at up to 35 sites in the United States, Canada, and Europe.
- The PULSAR study will enroll over 400 patients for treatment at up to 35 sites in the United States, Canada, and Europe.
- The study expands on the successful Globe System PULSE-EU study of 69 patients treated in Prague, Czech Republic.
- “As a next generation pulsed field system, the Globe System allows precise delivery of pulsed field energy.
- Kardium Inc. (kardium.com) is a rapidly growing, privately held medical solutions company that has developed an advanced system for atrial fibrillation (AF) treatment: the Globe® System.